Pamrevlumab
As of the edition of 20 October 2026, Pamrevlumab is an antibody: stopped in 2023; acts on CCN2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Antibody
- Registered trials
- 19, 10 stopped early
- Disease areas
- Hormones; Lungs and airways; Cancer; Digestive system; Bones, joints and muscles; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Pamrevlumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CCN2 | CCN family member 2 | P29279 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 5 | 4 | 0 | 1 |
| Phase 2 | 7 | 3 | 0 | 4 |
| Phase 3 | 6 | 2 | 0 | 4 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Kyntra Bio | Lead sponsor of trials | 2003 to now |